Affluent Medical SA(FR:CVX)
€4.85-0.09 (-1.82%)
FR:CVX
Affluent Medical SA financials statements
€4.85
At close:-0.09 (-1.82%)
Want to see FR:CVX full AI Analyst Report?
Affluent Medical SA (CVX) Ratios
1 Followers
Affluent Medical SA Ratios
FR:CVX's free cash flow for Q2 2026 was €-13.25M. For the 2026 fiscal year, FR:CVX's free cash flow was decreased by €-142.00K and operating cash flow was €-13.11M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.30 | 1.28 | 0.69 | 0.83 | 2.01 |
| Quick Ratio | 0.30 | 1.28 | 0.69 | 0.83 | 2.01 |
| Cash Ratio | 0.07 | 0.13 | 0.20 | 0.30 | 1.56 |
| Solvency Ratio | -0.54 | -0.40 | -0.54 | -0.49 | -0.47 |
| Operating Cash Flow Ratio | -0.49 | -1.19 | -1.43 | -1.28 | -1.69 |
| Short-Term Operating Cash Flow Coverage | -1.01 | -7.76 | -6.91 | -6.46 | -5.12 |
| Net Current Asset Value | € -35.17M | € -18.43M | € -19.36M | € -19.01M | € -11.82M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.50 | 0.27 | 0.30 | 0.30 | 0.28 |
| Debt-to-Equity Ratio | 4.33 | 0.54 | 0.54 | 0.52 | 0.45 |
| Debt-to-Capital Ratio | 0.81 | 0.35 | 0.35 | 0.34 | 0.31 |
| Long-Term Debt-to-Capital Ratio | 0.68 | 0.32 | 0.31 | 0.31 | 0.27 |
| Financial Leverage Ratio | 8.62 | 2.01 | 1.80 | 1.77 | 1.61 |
| Debt Service Coverage Ratio | -1.29 | -7.11 | -5.61 | -4.67 | -1.91 |
| Interest Coverage Ratio | 0.00 | -64.83 | -33.25 | -11.00 | -4.33 |
| Debt to Market Cap | 0.34 | 0.29 | 0.30 | 0.52 | 0.17 |
| Interest Debt Per Share | 0.61 | 0.42 | 0.60 | 1.00 | 1.23 |
| Net Debt to EBITDA | -1.41 | -1.12 | -1.16 | -1.15 | -0.77 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -225.16% | -98.04% | -82.45% | -88.90% |
| EBIT Margin | 0.00% | -384.63% | -1258.01% | -1169.83% | -917.16% |
| EBITDA Margin | 0.00% | -326.44% | -1090.11% | -986.86% | -750.38% |
| Operating Profit Margin | 0.00% | -380.99% | -1067.48% | -887.45% | -911.99% |
| Pretax Profit Margin | 0.00% | -390.51% | -1389.71% | -1150.11% | -1051.48% |
| Net Profit Margin | 0.00% | -357.92% | -1278.84% | -1137.19% | -1021.36% |
| Continuous Operations Profit Margin | 0.00% | -357.92% | -1278.84% | -1137.19% | -1021.36% |
| Net Income Per EBT | 96.00% | 91.65% | 92.02% | 98.88% | 97.14% |
| EBT Per EBIT | 144.51% | 102.50% | 130.19% | 129.60% | 115.30% |
| Return on Assets (ROA) | -52.21% | -24.22% | -27.64% | -25.37% | -21.16% |
| Return on Equity (ROE) | -449.85% | -48.69% | -49.74% | -45.01% | -34.04% |
| Return on Capital Employed (ROCE) | -73.93% | -30.57% | -27.11% | -23.13% | -21.09% |
| Return on Invested Capital (ROIC) | -48.28% | -27.10% | -23.91% | -21.98% | -19.63% |
| Return on Tangible Assets | -283.47% | -109.02% | -210.59% | -169.26% | -86.48% |
| Earnings Yield | -36.68% | -27.75% | -29.19% | -47.99% | -14.01% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 1.19 | 0.36 | 0.33 | 0.50 |
| Payables Turnover | 0.36 | 2.83 | 0.72 | 0.81 | 1.53 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 3.30 | 0.77 | 0.76 | 0.72 |
| Asset Turnover | 0.00 | 0.07 | 0.02 | 0.02 | 0.02 |
| Working Capital Turnover Ratio | 0.00 | -8236.00 | -0.60 | 0.45 | 0.53 |
| Cash Conversion Cycle | -1015.39 | 176.77 | 506.29 | 652.24 | 488.97 |
| Days of Sales Outstanding | 0.00 | 305.70 | 1014.19 | 1103.45 | 727.74 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1015.39 | 128.94 | 507.90 | 451.21 | 238.76 |
| Operating Cycle | 0.00 | 305.70 | 1014.19 | 1103.45 | 727.74 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.30 | -0.29 | -0.42 | -0.59 | -0.67 |
| Free Cash Flow Per Share | -0.30 | -0.29 | -0.42 | -0.59 | -0.68 |
| Dividend Paid and CapEx Coverage Ratio | -100.08 | -77.03 | -65.51 | -75.90 | -37.02 |
| Capital Expenditure Coverage Ratio | -100.08 | -77.03 | -65.51 | -75.90 | -37.02 |
| Operating Cash Flow Coverage Ratio | -0.48 | -0.69 | -0.70 | -0.62 | -0.63 |
| Operating Cash Flow to Sales Ratio | 0.00 | -2.75 | -9.85 | -8.28 | -8.52 |
| Free Cash Flow Yield | -17.22% | -21.60% | -22.82% | -35.38% | -12.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.75 | -3.60 | -3.43 | -2.08 | -7.14 |
| Price-to-Sales (P/S) Ratio | 0.00 | 12.90 | 43.81 | 23.70 | 72.91 |
| Price-to-Book (P/B) Ratio | 12.26 | 1.75 | 1.70 | 0.94 | 2.43 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.81 | -4.63 | -4.38 | -2.83 | -8.33 |
| Price-to-Operating Cash Flow Ratio | -5.86 | -4.69 | -4.45 | -2.86 | -8.56 |
| Price-to-Earnings Growth (PEG) Ratio | -0.04 | 0.11 | 0.10 | -1.67 | -1.83 |
| Enterprise Value Multiple | -5.72 | -5.07 | -5.18 | -3.55 | -10.48 |
| Enterprise Value | 90.37M | 68.22M | 69.10M | 46.88M | 114.13M |
| EV to EBITDA | -5.72 | -5.07 | -5.18 | -3.55 | -10.48 |
| EV to Sales | 0.00 | 16.57 | 56.46 | 35.01 | 78.66 |
| EV to Free Cash Flow | -7.71 | -5.95 | -5.65 | -4.18 | -8.99 |
| EV to Operating Cash Flow | -7.78 | -6.02 | -5.73 | -4.23 | -9.23 |
| Tangible Book Value Per Share | -0.85 | -0.43 | -0.61 | -0.91 | -0.50 |
| Shareholders’ Equity Per Share | 0.14 | 0.77 | 1.09 | 1.79 | 2.34 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.04 | 0.08 | 0.08 | 0.01 | 0.03 |
| Revenue Per Share | 0.00 | 0.10 | 0.04 | 0.07 | 0.08 |
| Net Income Per Share | -0.63 | -0.37 | -0.54 | -0.81 | -0.80 |
| Tax Burden | 0.96 | 0.92 | 0.92 | 0.99 | 0.97 |
| Interest Burden | 1.45 | 1.02 | 1.10 | 0.98 | 1.15 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.04 | 0.02 |
| SG&A to Revenue | 0.00 | 3.35 | 9.63 | 3.86 | 3.58 |
| Stock-Based Compensation to Revenue | 0.00 | 0.19 | 0.60 | 0.11 | 0.03 |
| Income Quality | 0.46 | 0.77 | 0.77 | 0.73 | 0.83 |
Currency in EUR
